All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find FDA Investigational New Drug (IND) Submissions for Gastroenterology

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

Country

News Type

Company

Product Type

Deal Size

refresh

Product Type

Companies

Biostage

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant

Contact the Supplier

Lead Product(s): Cellspan Esophageal Implant

Therapeutic Area: Gastroenterology

Highest Development Status: IND Enabling Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2020

Details:

The FDA notified the Company that it removed the clinical hold and that the Company may proceed with its study.

Anokion SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

Anokion Announces FDA Clearance of IND Application for its Lead Program in Celiac Disease

Contact the Supplier

Lead Product(s): KAN-101

Therapeutic Area: Gastroenterology

Highest Development Status: IND Enabling Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

Anokion plans to initiate its multi-center Phase 1 study for KAN-101 in people with celiac disease in the first quarter of 2020.